Emergent BioSolutions, Inc., dedicates new Baltimore facility

Emergent BioSolutions, Inc., dedicated a new $30 million facility in Baltimore, Maryland, on July 16 that is expected to add 120 new jobs to the area.

“It’s all about science, security, health and technology - all converging in the wonderful example of what Emergent BioSolutions is doing,” Maryland Governor Martin O’Malley said at the opening of the 56,000-square-foot facility. “As we confront a changing, uncertain world, Emergent BioSolutions demonstrates that global challenges are local opportunities.”

Governor O’Malley joined Baltimore City Council President Jack Young as well as staff from the offices of Senator Barbara Mikulski and Reps. Benjamin Cardin, Chris Van Hollen, and Dutch Ruppersberger. Corporate leaders included Parrish Galliher, CEO and founder of Xcellerex, whose company was a technology partner for Emergent, also attended the opening.

Based in Rockville, Maryland, Emergent BioSolutions, Inc., develops vaccines and antibody therapies. Emergent’s flagship anthrax vaccine, BioThrax, is the only vaccine currently licensed by the FDA to combat anthrax.

Dr. Judith Britz, executive director of the Maryland Biotechnology Center, an agency supporting the state’s biotechnology industry, underscored Emergent BioSolutions, Inc.'s importance.

“When you think about what this company does, they are protecting our soldiers, they are protecting us," Britz said.

The company’s product pipeline also include the research and development of vaccines for tuberculosis, chlamydia and typhoid. Ranked 23 on Forbes Magazine's top 200 small companies to work for, Emergent BioSolutions, Inc., is one of 500 biotechnology in Maryland that that provide employment for more than 30,000 people. 

Fuad El-Hibri, chairman and CEO of Emergent BioSolutions, Inc., said that the company was looking “to build on our core competency and establish an additional location for both commercial and clinical products.”

Citing the state’s thriving life-sciences industry and favorable business climate, El-Hibri indicated that choosing Maryland made sense across the board.

“This is a rich corridor where science, technology, and government intersect - much work can be done," El-Hibri said.

In coming to the Baltimore, Emergent is utilizing an existing location that previously housed an FDA licensed company. Initial re-outfitting costs are expected to be $15 million this year. with a final cost of $30 million by project completion in 2012. The building will feature a combination of traditional reactors and state-of the-art disposable manufacturing technologies.